IOL Chemicals misses paracetamol capacity target as it plans ₹1,400 cr capex
Management reaffirmed FY27 growth targets while admitting paracetamol utilization hit only 55%, lagging behind the 65% goal set for March.
— 3 earlier stories on IOL Chemicals And Pharmaceuticals Ltd. →What's new
- Paracetamol plant utilization reached 55%, missing the 65% target for March 2026.
- Management targets 70-75% utilization by FY27 and full capacity by FY28.
- IOL plans a phased ₹1,200-1,400 crore greenfield capex over five years.
Why this matters
The gap between the target and actual utilization in the paracetamol segment suggests execution pressure. While management remains optimistic about long-term capacity ramp-ups, the heavy capex plan relies entirely on internal accruals, leaving little room for error if demand growth stalls.
What we're watching
- Quarterly updates on paracetamol utilization to track the path to 70%.
- Progress on the non-ibuprofen portfolio expansion in European markets.
- Cash flow generation to support the multi-year ₹1,400 crore capex.
The full read
IOL Chemicals is betting on a massive ₹1,200-1,400 crore greenfield expansion to drive its next phase of growth. The plan spans the next five years and relies entirely on internal accruals.
Execution is lagging.
Its 10,800-tonne paracetamol plant is currently running at 55% utilization, failing to meet the 65% target set for March 2026. Management claims a path to 70-75% by FY27 and full capacity by FY28, but the current shortfall is a clear hurdle. Meanwhile, Ibuprofen demand has rebounded to 85-95% utilization after a destocking cycle, and the non-ibuprofen portfolio is gaining traction in Europe. Management reaffirmed its FY27 guidance of 15-18% revenue growth and a 14% EBITDA margin, up from 12.4% in FY26. The next test is whether the company can bridge the utilization gap while simultaneously funding its heavy capital expenditure program without straining its balance sheet.
Questions answered
- What is the status of the paracetamol plant?
- Utilization stands at 55% on the 10,800-tonne capacity, which is below the 65% target management previously set for March 2026.
- How does management plan to fund the new greenfield capex?
- The company intends to fund the ₹1,200-1,400 crore investment through internal accruals over the next four to five years.
- What is the outlook for Ibuprofen demand?
- Demand has recovered to 85-95% utilization following the completion of a destocking cycle.
- What are the company's financial targets for FY27?
- Management expects revenue growth of 15-18% and an EBITDA margin of 14%, an improvement from the 12.4% recorded in FY26.
Story so far
All notes on IOLCP →- 22 May 2026 · 4:31 PM IST IOL Chemicals misses paracetamol capacity target as it plans ₹1,400 cr capex
- today IOL Chemicals files transcript of May 22 earnings call
- 7d ago IOL Chem's Q4 & FY26 results: Old news, no surprises
- 8d ago IOL Chemicals hits record Q4 revenue of ₹619.5 cr, PAT up 68%